Graft Versus Host Disease – Epidemiology – Epidemiology – Graft Versus Host Disease – Mature Markets
Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets and the emerging pharmaceutical markets. We report both the incidence of GVHD for each country and annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s GVHD forecast will answer the following questions:
- Of all people diagnosed with GVHD, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GVHD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 29 GVHD patient populations, including the following:
- Diagnosed events of allogenic HSCT.
- Diagnosed incident cases of acute GVHD by severity.
- Diagnosed incident cases of chronic GVHD by severity.
- Diagnosed acute GVHD: severity subpopulation(s).
- Diagnosed chronic GVHD: severity subpopulation(s).
- Diagnosed lifetime prevalent cases of chronic GVHD.
- Diagnosed lifetime prevalent cases of chronic GVHD by severity.
- Diagnosed drug-treated cases of acute GVHD.
- Diagnosed drug-treated cases of acute GVHD by severity.
- Diagnosed drug-treated cases of chronic GVHD.
- Diagnosed drug-treated cases of chronic GVHD by severity.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Graft Versus Host Disease - Epidemiology - Epidemiology - Graft Versus Host Disease - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of graft versus host disease)
- Diagnosed events of allogeneic hematopoietic stem-cell transplantation
- Diagnosed incident cases of acute graft versus host disease
- Diagnosed incident cases of chronic graft versus host disease
- Diagnosed lifetime prevalent cases of chronic graft versus host disease
- Diagnosed incident cases of acute graft versus host disease by severity
- Diagnosed incident cases of chronic graft versus host disease by severity
- Diagnosed lifetime prevalent cases of chronic graft versus host disease by severity
- Drug-treated prevalent cases of chronic graft versus host disease and incident cases of acute and chronic graft versus host disease
- Risk / protective factors applied to disease forecast models
- Reference materials
